NEW YORK, April 24 /PRNewswire-FirstCall/ -- PulmoBioTech Inc. (OTC
Bulletin Board: PLMO) announced today that its PulmoScience subsidiary has
released details of the areas that it will be investigating as part of the
Regulatory Approval Experiments for Human Trials. The areas are:
1. Efficacy Binding Studies
2. Characterization of Drug Product Impurities
3. Sterility Studies
5. Immunological Testing
PulmoScience will be completing all the relevant tests in each area and seeking Regulatory sign-off before starting the detailed Human Trials. This is currently expected to be achieved in the first half of 2008.
About PulmoBioTech Inc.
PulmoBioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized field, and work with a broad range of investment institutions. PulmoBioTech's mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stock holders.
About PulmoScience Inc.
PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind.
The company was conceived within the Montreal Heart Institute "MHI" (a
world renowned hospital and educational facility). Jointly owned by MHI
subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn
Dupuis (the scientific director and originator of the PulmoBind Molecular
Imaging technology), and by PulmoBioTech Inc. as the funding partner,
PulmoScience Inc. aims to develop this unique and ex
|SOURCE PulmoBioTech Inc.|
Copyright©2008 PR Newswire.
All rights reserved